Clinical Scorecard: Impact of Cushing Syndrome Treatment on Lipid Abnormalities: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Cushing syndrome (CS), characterized by chronic excess of endogenous or exogenous glucocorticoids causing metabolic and cardiovascular complications
Key Mechanisms
Excess glucocorticoids induce dyslipidemia by stimulating preadipocyte differentiation and hepatic cholesterol/fatty acid synthesis, leading to elevated triglycerides, total cholesterol, and LDL cholesterol
Target Population
Patients with endogenous Cushing syndrome undergoing surgical or medical treatment
Care Setting
Endocrinology and metabolic clinics managing hypercortisolism and its cardiovascular/metabolic complications
Key Highlights
Treatment of CS significantly decreases serum total cholesterol, LDL cholesterol, and triglycerides but does not significantly change HDL cholesterol levels
Greater lipid improvements observed in patients with adrenal hypercortisolism, those treated with steroidogenesis inhibitors, and with treatment duration ≥12 months
CS treatment also improves blood glucose levels, body mass index, waist circumference, and insulin resistance indices
Guideline-Based Recommendations
Diagnosis
Evaluate lipid profile at diagnosis and periodically after in all cases of endogenous hypercortisolism due to high prevalence of dyslipidemia
Management
Prompt treatment of dyslipidemia is mandatory in CS patients to reduce cardiovascular risk
Treatment options include surgical (pituitary, ectopic, adrenal), pharmacological (steroidogenesis inhibitors, ketoconazole, pasireotide, mifepristone), or radiotherapy approaches
Be aware that some treatments like mitotane may increase cholesterol and triglycerides, whereas ketoconazole reduces LDL cholesterol
Monitoring & Follow-up
Regular monitoring of serum lipid levels, glucose metabolism parameters, anthropometric measures, and insulin resistance is recommended during and after CS treatment
Risks
CS patients have increased cardiovascular risk due to combined effects of hypercortisolism, metabolic syndrome, and prothrombotic state
Treatment-related effects on lipids vary by therapy type and duration; some agents may worsen lipid profile
Patient & Prescribing Data
Patients with endogenous Cushing syndrome undergoing treatment
Steroidogenesis inhibitors and longer treatment duration (≥12 months) are associated with greater improvements in lipid profiles; ketoconazole reduces LDL cholesterol by ~25%; mitotane may increase lipids
Clinical Best Practices
Assess and monitor lipid profiles routinely in CS patients before and after treatment
Select treatment modalities considering their differential impact on lipid metabolism
Address coexisting metabolic abnormalities such as obesity, insulin resistance, and hyperglycemia alongside dyslipidemia
Consider cardiovascular risk stratification and implement preventive measures accordingly
Further research needed to confirm if lipid improvements translate into reduced major cardiovascular events
A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.
